Mar 11, 2025 | Drug costs, GLP-1s, Health care costs, Ozempic, Pharmacy, Rx Costs, Wegovy, Weight loss, Weight loss drugs, Zepbound
The end of shortages on Ozempic, Wegovy, and other semaglutide injections could place added pressure on self-funded health plans to cover the costs of the high-priced medications. On February 21, the FDA confirmed that the supply of GLP-1 drugs used to treat obesity...
Sep 3, 2024 | Biosimilars, Cost Savings, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Savings, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
May 13, 2024 | Diabetes, Kurt Harden, MedBen Rx, MedBen University, Mounjaro, Ozempic, Wegovy, Weight loss, Zepbound
At recent MedBen University roundtables, MedBen President & CEO Kurt Harden examined how the growing public awareness of two diabetes drugs with a desirable side effect – significant weight loss – means that these $1,000-per-month medications are not always being...
Sep 18, 2023 | Announcements, ICD-10 diagnosis code, MedBen Rx, Ozempic, Prescription, Ventegra
Important information for MedBen Rx clients using the Ventegra formulary: Effective October 1, an appropriate ICD-10 diagnosis code for type 2 diabetes will be required for certain Ozempic prescriptions and all other GLP-1 class medications. Ozempic and other GLP-1...
Jul 21, 2023 | Diabetes, Medicare, Ozempic, Pharmacy, Prescription, Research, Trulicity, Weight loss
A Kaiser Family Foundation (KFF) analysis of the 10 top-selling prescription drugs under Medicare Part D offers an interesting snapshot of pharmacy spend. The drugs in question comprised less than 1% of all covered drugs in 2021, but made up approximately 22% of total...
Jun 15, 2023 | Obesity, Ozempic, Pharmacy, Prescription, Rx Costs, Semaglutide, Wegovy, Weight loss
Obesity drugs are becoming big business, with a correspondingly big price tag. And with these drugs regularly making headlines, questions about whether or not health plans should cover them grow louder. The highest-profile obesity drug is semaglutide, sold under the...
